Drug class
Non-ergoline dopamine D2/D3 receptor agonist; antiparkinsonian agent
Mechanism of action
Stimulates central dopamine D2-family receptors, particularly D2 and D3 receptors, thereby enhancing dopaminergic neurotransmission in motor pathways involved in Parkinson’s disease.
General use cases
- Symptomatic treatment of Parkinson’s disease, as monotherapy or in combination with levodopa, according to the relevant product authorisation.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
